GRAIL ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4)
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has announced the granting of equity awards to 55 recently hired non-executive employees. These awards, in the form of restricted stock units (RSUs) totaling 182,223 shares of GRAIL's common stock, were granted under the company's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs are designed to vest over approximately four years, with 25% vesting in either May or August 2025, depending on the employee's start date, and the remaining vesting annually thereafter. This vesting schedule is subject to continued employment with GRAIL or its subsidiaries.
GRAIL, Inc. (Nasdaq: GRAL), un'azienda nel settore sanitario focalizzata sulla rilevazione precoce del cancro, ha annunciato la concessione di premi azionari a 55 nuovi dipendenti non esecutivi. Questi premi, sotto forma di unità azionarie ristrette (RSU) per un totale di 182.223 azioni ordinarie di GRAIL, sono stati concessi nell'ambito del piano di incentivazione azionaria per l'induzione in conformità con la Regola di quotazione 5635(c)(4) di Nasdaq.
Le RSU sono progettate per maturare in circa quattro anni, con il 25% che matura a maggio o agosto 2025, a seconda della data di assunzione del dipendente, e il restante matura annualmente successivamente. Questa programmazione di maturazione è soggetta al mantenimento dell'impiego con GRAIL o le sue filiali.
GRAIL, Inc. (Nasdaq: GRAL), una empresa de atención médica enfocada en la detección temprana del cáncer, ha anunciado la concesión de premios de acciones a 55 empleados no ejecutivos recientemente contratados. Estos premios, en forma de unidades de acciones restringidas (RSUs) que totalizan 182,223 acciones comunes de GRAIL, fueron otorgados bajo el Plan de Incentivo de Equidad por Inducción de la empresa de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq.
Las RSUs están diseñadas para adquirir derechos durante aproximadamente cuatro años, con el 25% adquiriendo derechos en mayo o agosto de 2025, dependiendo de la fecha de inicio del empleado, y el resto adquiriendo derechos anualmente después. Este cronograma de adquisición está sujeto a la continuación del empleo con GRAIL o sus subsidiarias.
GRAIL, Inc. (Nasdaq: GRAL), 조기 암 발견에 주력하는 헬스케어 회사는 최근 고용된 비임원 직원 55명에게 주식 보상을 부여했다고 발표했습니다. 이 보상은 GRAIL의 보통주 총 182,223주로 구성된 제한주식단위 (RSUs) 형태로, Nasdaq 상장 규정 5635(c)(4)에 따라 회사의 유도 주식 인센티브 계획에 따라 지급되었습니다.
RSU는 약 4년 동안 배분되도록 설계되었으며, 25%는 직원의 시작 날짜에 따라 2025년 5월 또는 8월에 배분되고, 나머지는 그 이후 매년 배분됩니다. 이 배분 일정은 GRAIL 또는 그 자회사에서 계속 고용되는 조건에 따라 달라집니다.
GRAIL, Inc. (Nasdaq: GRAL), une entreprise de santé axée sur la détection précoce du cancer, a annoncé l'octroi de prix en actions à 55 employés non exécutifs récemment embauchés. Ces prix, sous forme d'unités d'actions restreintes (RSUs) totalisant 182 223 actions ordinaires de GRAIL, ont été accordés dans le cadre du Plan d'incitation en actions pour induction de la société conformément à la règle d'inscription Nasdaq 5635(c)(4).
Les RSUs sont conçues pour parvenir à maturation sur une période d'environ quatre ans, avec 25 % qui arriveront à maturation en mai ou août 2025, selon la date de début de l'employé, et le reste arrivera à maturation annuellement par la suite. Ce calendrier de maturation est soumis au maintien de l'emploi avec GRAIL ou ses filiales.
GRAIL, Inc. (Nasdaq: GRAL), ein Gesundheitsunternehmen, das sich auf die frühe Erkennung von Krebs konzentriert, hat die Gewährung von Aktienprämien an 55 neu eingestellte nicht-executive Mitarbeiter bekannt gegeben. Diese Prämien, in Form von Restricted Stock Units (RSUs), die insgesamt 182.223 Aktien des Stammkapitals von GRAIL ausmachen, wurden im Rahmen des Aktienanreizplans des Unternehmens gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt.
Die RSUs sind so gestaltet, dass sie über einen Zeitraum von etwa vier Jahren verfallen, wobei 25 % entweder im Mai oder im August 2025 verfallen, abhängig vom Einstiegsdatum des Mitarbeiters, und der restliche Anteil danach jährlich verfällt. Dieser Vesting-Zeitplan steht unter dem Vorbehalt einer fortgesetzten Beschäftigung bei GRAIL oder deren Tochtergesellschaften.
- Granting of equity awards to attract new talent
- Alignment of employee interests with company growth through RSUs
- Potential dilution of existing shareholders' equity
The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of GRAIL, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with GRAIL, pursuant to Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over an approximately four year period, with
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302235336.html
SOURCE GRAIL, Inc.
FAQ
How many shares of GRAL stock were granted as RSUs to new employees?
What is the vesting schedule for the RSUs granted by GRAIL (GRAL)?
Under which plan were the GRAIL (GRAL) equity awards granted?
What is the purpose of GRAIL's (GRAL) equity awards to new employees?
